The endothelium controls vascular tone not only by releasing NO and prostacyclin, but also by other pathways causing hyperpolarization of the underlying smooth muscle cells. This characteristic was at the origin of the term ‘endothelium-derived hyperpolarizing factor’ (EDHF). However, this acronym includes different mechanisms. Arachidonic acid metabolites derived from the cyclo-oxygenases, lipoxygenases and cytochrome P450 pathways, H2O2, CO, H2S and various peptides can be released by endothelial cells. These factors activate different families of K+ channels and hyperpolarization of the vascular smooth muscle cells contribute to the mechanisms leading to their relaxation. Additionally, another pathway associated with the hyperpolarization of both endothelial and vascular smooth muscle cells contributes also to endothelium-dependent relaxations (EDHF-mediated responses). These responses involve an increase in the intracellular Ca2+ concentration of the endothelial cells, followed by the opening of SKCa and IKCa channels (small and intermediate conductance Ca2+-activated K+ channels respectively). These channels have a distinct subcellular distribution: SKCa are widely distributed over the plasma membrane, whereas IKCa are preferentially expressed in the endothelial projections toward the smooth muscle cells. Following SKCa activation, smooth muscle hyperpolarization is preferentially evoked by electrical coupling through myoendothelial gap junctions, whereas, following IKCa activation, K+ efflux can activate smooth muscle Kir2.1 and/or Na+/K+-ATPase. EDHF-mediated responses are altered by aging and various pathologies. Therapeutic interventions can restore these responses, suggesting that the improvement in the EDHF pathway contributes to their beneficial effect. A better characterization of EDHF-mediated responses should allow the determination of whether or not new drugable targets can be identified for the treatment of cardiovascular diseases.
Skip Nav Destination
Article navigation
August 2009
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
Review Article|
July 16 2009
EDHF: an update
Michel Félétou;
*Department of Angiology, Institut de Recherches Servier, 92150 Suresnes, France
Correspondence: Dr Michel Félétou (email [email protected]).
Search for other works by this author on:
Paul M. Vanhoutte
Paul M. Vanhoutte
†Department of Pharmacology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
February 16 2009
Revision Received:
March 30 2009
Accepted:
April 09 2009
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2009 Biochemical Society
2009
Clin Sci (Lond) (2009) 117 (4): 139–155.
Article history
Received:
February 16 2009
Revision Received:
March 30 2009
Accepted:
April 09 2009
Citation
Michel Félétou, Paul M. Vanhoutte; EDHF: an update. Clin Sci (Lond) 1 August 2009; 117 (4): 139–155. doi: https://doi.org/10.1042/CS20090096
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |